An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia [0.03%]
艾加蒙洛珠单抗治疗镰状细胞病和输血依赖型β-地中海贫血的疗效评估
Rupert Handgretinger,Markus Mezger
Rupert Handgretinger
Introduction: Sickle cell disease is the most common hereditary hemoglobinopathy followed by beta-thalassemia. Until recently, allogeneic stem cell transplantation was the only curative approach. Based on the Crispr-Cas9-...
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors [0.03%]
克服CAR-T细胞治疗在抗原异质性实体瘤中效率限制的方法
Astero Klampatsa
Astero Klampatsa
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement [0.03%]
靶向T细胞的双特异性抗体治疗多发性骨髓瘤：现有知识及持续活化T细胞的未来策略
Marise R Heerma van Voss,Remco J Molenaar,Charlotte L B M Korst et al.
Marise R Heerma van Voss et al.
Introduction: T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein - coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the treatment of...
Edward Tobinick,Danielle Ucci,Kirsten Bermudo et al.
Edward Tobinick et al.
Introduction: Perispinal etanercept (PSE) is an innovative treatment designed to improve stroke recovery by addressing chronic post-stroke neuroinflammation. Basic science evidence, randomized clinical trial (RCT) evidenc...
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma [0.03%]
免疫疗法目前在治疗转移性和局部晚期胃食管腺癌中的应用及未来展望
Izuma Nakayama,Kohei Shitara
Izuma Nakayama
Introduction: Immunochemotherapy with PD-1 blockade has been established as the current standard first-line therapy for patients with mGEA. Reviewing the history of clinical trials offers valuable insight into the evoluti...
Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis [0.03%]
基于干细胞的治疗和临床前研究在肌萎缩侧索硬化中的现状及新途径
Letizia Mazzini,Fabiola De Marchi,Leonora Buzanska et al.
Letizia Mazzini et al.
Introduction: Cell therapy development represents a critical challenge in amyotrophic lateral sclerosis (ALS) research. Despite more than 20 years of basic and clinical research, no definitive safety and efficacy results ...
Eric Toussirot,Renaud Felten
Eric Toussirot
Introduction: The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spondyloarthri...
The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process [0.03%]
杜氏肌营养不良症基因治疗药物delandistrogene moxeparvovec-rokl的FDA审批：对证据和监管过程的批判性评估
Mehul Bhattacharyya,Larry E Miller,Anna L Miller et al.
Mehul Bhattacharyya et al.
How comparative studies can inform treatment decisions for Crohn's disease [0.03%]
循证研究如何指导克罗恩病的治疗决策？
Giuseppe Privitera,Cristina Bezzio,Arianna Dal Buono et al.
Giuseppe Privitera et al.
Introduction: As new therapies for the treatment of Crohn's disease (CD) are approved, there is an increasing need for evidence that clarifies their positioning and sequencing. ...
C Siverino,W-J Metsemakers,R Sutter et al.
C Siverino et al.
Introduction: With the introduction and continuous improvement in operative fracture fixation, even the most severe bone fractures can be treated with a high rate of successful healing. However, healing complications can ...